Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes

British Journal of Haematology

Volumn 137, Issue 2, 2007, Pages 125-132

  Golshayan, Ali Reza ^a   Jin, Tao ^a   Maciejewski, Jaroslaw ^a   Fu, Alex Z ^a   Bershadsky, Boris ^a   Kattan, Michael W ^a   Kalaycio, Matt E ^a   Sekeres, Mikkael A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Growth factors; Myelodysplastic syndrome; Outcome; Treatment

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLARUBICIN; ALITRETINOIN; ALPHA INTERFERON; AMIFOSTINE; AZACITIDINE; CALCITRIOL; CYCLOSPORIN; CYTARABINE; DANAZOL; ERYTHROPOIETIN; ETANERCEPT; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEXAMETHYLENEBISACETAMIDE; IDARUBICIN; INFLIXIMAB; INTERLEUKIN 3; INTERLEUKIN 6; ISOTRETINOIN; LENALIDOMIDE; MENATETRENONE; PENTOXIFYLLINE; RAPAMYCIN; RETINOIC ACID; THALIDOMIDE; THYMOCYTE ANTIBODY; TIPIFARNIB;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDLINE; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GROWTH SUBSTANCES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33947499579     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06546.x     Document Type: Article

References (35)

1. Bennett, J.M., Catovsky, D., Daniel, M.T., Flandrin, G., Galton, D.A., Gralnick, H.R. & Sultan, C. (1982) Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology, 51, 189-199.
2. Bowen, D., Culligan, D., Jowitt, S., Kelsey, S., Mufti, G., Oscier, D. & Parker, J. (2003) Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. British Journal of Haematology, 120, 187-200.
3. Bowen, D., MacIlwaine, L., Cavanagh, J., Killick, S., Culligan, D., Thomson, E. & Mufti, G. (2005) Thalidomide therapy for low-risk Myelodysplasia. Leukemia Research, 29, 235-236.
4. Casadevall, N., Durieux, P., Dubois, S., Hemery, F., Lepage, E., Quarre, M.C., Damaj, G., Giraudier, S., Guerci, A., Laurent, G., Dombret, H., Chomienne, C., Ribrag, V., Stamatoullas, A., Marie, J.P., Vekhoff, A., Maloisel, F., Navarro, R., Dreyfus, F. & Fenaux, P. (2004) Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood, 104, 321-327.
5. Cheson, B.D., Bennett, J.M., Kantarjian, H., Pinto, A., Schiffer, C.A., Nimer, S.D., Lowenberg, B., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Wijermans, P.W., Gore, S. & Greenberg, P.L. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 96, 3671-3674.
6. Cheson, B.D., Greenberg, P.L., Bennett, J.M., Lowenberg, B., Wijermans, P.W., Nimer, S.D., Pinto, A., Beran, M., de Witte, T.M., Stone, R.M., Mittelman, M., Sanz, G.F., Gore, S.D., Schiffer, C.A. & Kantarjian, H. (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood, 108, 419-425.
7. Clark, R.E., Jacobs, A., Lush, C.J. & Smith, S.A. (1987) Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome. Lancet, 1, 763-765.
8. Cutler, C.S., Lee, S.J., Greenberg, P., Deeg, H.J., Perez, W.S., Anasetti, C., Bolwell, B.J., Cairo, M.S., Gale, R.P., Klein, J.P., Lazarus, H.M., Liesveld, J.L., McCarthy, P.L., Milone, G.A., Rizzo, J.D., Schultz, K.R., Trigg, M.E., Keating, A., Weisdorf, D.J., Antin, J.H. & Horowitz, M.M. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 104, 579-585.
9. Foucar, K., Langdon, II, R.M., Armitage, J.O., Olson, D.B. & Carroll, Jr, T.J. (1985) Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer, 56, 553-561.
10. Germing, U., Gattermann, N., Strupp, C., Aivado, M. & Aul, C. (2000) Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leukemia Research, 24, 983-992.
11. Greenberg, P., Cox, C., LeBeau, M.M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., Ohyashiki, K., Toyama, K., Aul, C., Mufti, G. & Bennett, J. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood, 89, 2079-2088.
12. Harris, N.L., Jaffe, E.S., Diebold, J., Flandrin, G., Muller-Hermelink, H.K., Vardiman, J., Lister, T.A. & Bloomfield, C.D. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
13. Hellstrom-Lindberg, E. (1995) Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. British Journal of Haematology, 89, 67-71.
14. Hellstrom-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I.M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Nilsson-Ehle, H., Samuelsson, J., Tangen, J.M., Winqvist, I., Oberg, G., Osterborg, A. & Ost, A. (1998) Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood, 92, 68-75.
15. Hellstrom-Lindberg, E., Gulbrandsen, N., Lindberg, G., Ahlgren, T., Dahl, I.M., Dybedal, I., Grimfors, G., Hesse-Sundin, E., Hjorth, M., Kanter-Lewensohn, L., Linder, O., Luthman, M., Lofvenberg, E., Oberg, G., Porwit-MacDonald, A., Radlund, A., Samuelsson, J., Tangen, J.M., Winquist, I. & Wisloff, F. (2003) A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology, 120, 1037-1046.
16. Howe, R.B., Porwit-MacDonald, A., Wanat, R., Tehranchi, R. & Hellstrom-Lindberg, E. (2004) The WHO classification of MDS does make a difference. Blood, 103, 3265-3270.
17. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes (1998) A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. British Journal of Haematology, 103, 1070-1074.
18. Jadersten, M., Montgomery, S.M., Dybedal, I., Porwit-MacDonald, A. & Hellstrom-Lindberg, E. (2005) Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood, 106, 803-811.
19. Koeffler, H.P., Heitjan, D., Mertelsmann, R., Kolitz, J.E., Schulman, P., Itri, L., Gunter, P. & Besa, E. (1988) Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood, 71, 703-708.
20. Kuendgen, A., Strupp, C., Aivado, M., Bernhardt, A., Hildebrandt, B., Haas, R., Germing, U. & Gattermann, N. (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood, 104, 1266-1269.
21. Larson, R.A. (2006) Myelodysplasia: when to treat and how. Best Practice & Research. Clinical Haematology, 19, 293-300.
22. List, A., Kurtin, S., Roe, D.J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R. & Zeldis, J.B. (2005) Efficacy of lenalidomide in myelodysplastic syndromes. New England Journal of Medicine, 352, 549-557.
23. Malcovati, L., Porta, M.G., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., Lazzarino, M. & Cazzola, M. (2005) Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology, 23, 7594-7603.
24. Mantovani, L., Lentini, G., Hentschel, B., Wickramanayake, P.D., Loeffler, M., Diehl, V. & Tesch, H. (2000) Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. British Journal of Haematology, 109, 367-375.
25. Miller, K. (1998) Erythropoietin, with and without granulocyte-colony stimulating factor (G-CSF), in the treatment of myelodysplastic syndrome (MDS) patients. Leukemia Research, 22(Suppl. 1), S13-16.
26. Miller, K.B., Kim, K., Morrison, F.S., Winter, J.N., Bennett, J.M., Neiman, R.S., Head, D.R., Cassileth, P.A. & O'Connell, M.J. (1992) The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Annals of Hematology, 65, 162-168.
27. Mittelman, M. & Lessin, L.S. (1994) Clinical application of recombinant erythropoietin in myelodysplasia. Hematology/oncology Clinics of North America, 8, 993-1009.
28. Musto, P., Falcone, A., Sanpaolo, G., Bodenizza, C., La Sala, A., Perla, G. & Carella, A.M. (2003) Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. British Journal of Haematology, 122, 269-271.
29. Negrin, R.S., Stein, R., Doherty, K., Cornwell, J., Vardiman, J., Krantz, S. & Greenberg, P.L. (1996) Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood, 87, 4076-4081.
30. Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P. & Zeldis, J. (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 98, 958-965.
31. Shimamoto, T., Tohyama, K., Okamoto, T., Uchiyama, T., Mori, H., Tomonaga, M., Asano, Y., Niho, Y., Teramura, M., Mizoguchi, H., Omine, M. & Ohyashiki, K. (2003) Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leukemia Research, 27, 783-788.
32. Silverman, L.R., Demakos, E.P., Peterson, B.L., Kornblith, A.B., Holland, J.C., Odchimar-Reissig, R., Stone, R.M., Nelson, D., Powell, B.L., DeCastro, C.M., Ellerton, J., Larson, R.A., Schiffer, C.A. & Holland, J.F. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology, 20, 2429-2440.
33. Stadler, M., Germing, U., Kliche, K.O., Josten, K.M., Kuse, R., Hofmann, W.K., Schrezenmeier, H., Novotny, J., Anders, O., Eimermacher, H., Verbeek, W., Kreipe, H.H., Heimpel, H., Aul, C. & Ganser, A. (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia, 18, 460-465.
34. Terpos, E., Mougiou, A., Kouraklis, A., Chatzivassili, A., Michalis, E., Giannakoulas, N., Manioudaki, E., Lazaridou, A., Bakaloudi, V., Protopappa, M., Liapi, D., Grouzi, E., Parharidou, A., Symeonidis, A., Kokkini, G., Laoutaris, N.P., Vaipoulos, G., Anagnostopoulos, N.I., Christakis, J.I., Meletis, J., Bourantas, K.L., Zoumbos, N.C., Yataganas, X. & Viniou, N.A. (2002) Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. British Journal of Haematology, 118, 174-180.
35. Wallvik, J., Stenke, L., Bernell, P., Nordahl, G., Hippe, E. & Hast, R. (2002) Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. European Journal of Haematology, 68, 180-185.